Do circulating concentrations of Galectin-3 reflect endomyocardial Galectin-3 levels or cardiac fibrosis in patients with heart failure?
Circulating Galectin-3 levels do not accurately reflect myocardial Galectin-3 levels or cardiac fibrosis in heart failure patients, limiting its utility as a direct systemic biomarker for these specific cardiac processes.
The present study suggests that myocardial Gal-3 can be considered as a possible marker for both cardiac inflammation and fibrosis, depending on the pathogenesis of heart failure. However, circulating concentrations of Gal-3 do not seem to reflect endomyocardial Gal-3 levels or cardiac fibrosis.
Besler et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: